ONC:NASDAQ
BeOne Medicines AG
$354.47
arrow_upward
+1.24%(+4.34) 1D
Oct 9, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
$348.00
High
$357.14
Low
$347.72
Mkt. cap
42.40B
Avg. vol.
375.94K
Volume
0.00
52-wk high
$385.22
52-wk low
$253.95
Beta
0.61
Shares outstanding
109.79M
No. of employees
12K
Open
$348.00
High
$357.14
Low
$347.72
Mkt. cap
42.40B
Avg. vol.
375.94K
Volume
0.00
52-wk high
$385.22
52-wk low
$253.95
Beta
0.61
Shares outstanding
109.79M
No. of employees
12K
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 week ago
ONC Q2 2026 Earnings: Reported EPS of 13.8375 as Shares Slip 0.2% - Basic EPS Analysis
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com